Method comparison of dipeptidyl peptidase IV activity assays and their application in biological samples containing reversible inhibitors

Clinica Chimica Acta

Volumn 413, Issue 3-4, 2012, Pages 456-462

  Matheeussen, Veerle ^a   Lambeir, Anne Marie ^a   Jungraithmayr, Wolfgang ^b   Gomez, Nelson ^c   Mc Entee, Kathleen ^c   Van der Veken, Pieter ^a   Scharpé, Simon ^a   De Meester, Ingrid ^a  

^a UNIVERSITY OF ANTWERP   (Belgium)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^c UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

Author keywords

CD26; DPP4; DPPIV inhibitors; Method validation; Preclinical studies; Vildagliptin

Indexed keywords

DIPEPTIDYL PEPTIDASE IV; DIPEPTIDYL PEPTIDASE IV INHIBITOR; VILDAGLIPTIN;

ACCURACY; ARTICLE; BLOOD SAMPLING; COLORIMETRY; CONTROLLED STUDY; DILUTION; ENZYME ACTIVITY; FLUOROMETRY; INTERMETHOD COMPARISON; LUMINESCENCE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SENSITIVITY AND SPECIFICITY;

ANALYTIC SAMPLE PREPARATION METHODS; ANIMALS; COLORIMETRY; DIPEPTIDYL PEPTIDASE 4; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; ENZYME ASSAYS; FLUOROMETRY; HUMANS; KINETICS; LINEAR MODELS; MICE;

EID: 84355166409     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2011.10.031     Document Type: Article

References (41)

1. Durinx C., Lambeir A.M., Bosmans E., et al. Molecular characterization of dipeptidyl peptidase activity in serum: soluble CD26/dipeptidyl peptidase IV is responsible for the release of X-Pro dipeptides. Eur J Biochem 2000, 267:5608-5613.
2. Hopsu-Havu V.K., Glenner G.G. A new dipeptide naphthylamidase hydrolyzing glycyl-prolyl-beta-naphthylamide. Histochemie 1966, 7:197-201.
3. De Meester I., Scharpé S., Lambeir A.M. Dipeptidyl peptidases and related proteins: multifaceted markers and therapeutic targets. Clin Chem Lab Med 2009, 47:245-247.
4. Lambeir A.M., Scharpe S., De Meester I. DPP4 inhibitors for diabetes-what next?. Biochem Pharmacol 2008, 76:1637-1643.
5. Deacon C.F. Dipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes: a comparative review. Diabetes Obes Metab 2011, 13:7-18.
6. Nagatsu T., Hino M., Fuyamada H., Hayakawa T., Sakakibara S. New chromogenic substrates for X-prolyl dipeptidyl-aminopeptidase. Anal Biochem 1976, 74:466-476.
7. Kato T., Nagatsu T., Kimura T., Sakakibara S. Fluorescence assay of x-prolyl dipeptidyl-aminopeptidase activity with a new fluorogenic substrate. Biochem Med 1978, 19:351-359.
8. Kim D., Wang L., Beconi M., et al. (2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin -7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine: a potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. J Med Chem 2005, 48:141-151.
9. Villhauer E.B., Brinkman J.A., Naderi G.B., et al. 1-[[(3-hydroxy-1-adamantyl)amino]acetyl]-2-cyano-(S)-pyrrolidine: a potent, selective, and orally bioavailable dipeptidyl peptidase IV inhibitor with antihyperglycemic properties. J Med Chem 2003, 46:2774-2789.
10. Augeri D.J., Robl J.A., Betebenner D.A., et al. Discovery and preclinical profile of Saxagliptin (BMS-477118): a highly potent, long-acting, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. J Med Chem 2005, 48:5025-5037.
11. Eckhardt M., Langkopf E., Mark M., et al. 8-(3-(R)-aminopiperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin -2-ylmethyl)-3,7-dihydropurine-2,6-dione (BI 1356), a highly potent, selective, long-acting, and orally bioavailable DPP-4 inhibitor for the treatment of type 2 diabetes. J Med Chem 2007, 50:6450-6453.
12. Edmondson S.D., Mastracchio A., Duffy J.L., et al. Discovery of potent and selective orally bioavailable beta-substituted phenylalanine derived dipeptidyl peptidase IV inhibitors. Bioorg Med Chem Lett 2005, 15:3048-3052.
13. Pospisilik J.A., Stafford S.G., Demuth H.U., et al. Long-term treatment with the dipeptidyl peptidase IV inhibitor P32/98 causes sustained improvements in glucose tolerance, insulin sensitivity, hyperinsulinemia, and beta-cell glucose responsiveness in VDF (fa/fa) Zucker rats. Diabetes 2002, 51:943-950.
14. Dubois V., Lambeir A.M., Van der Veken P., et al. Purification and characterization of dipeptidyl peptidase IV-like enzymes from bovine testes. Front Biosci 2008, 13:3558-3568.
15. Matheeussen V., Baerts L., De Meyer G., et al. Expression and spatial heterogeneity of dipeptidyl peptidases in endothelial cells of conduct vessels and capillaries. Biol Chem 2011, 392:189-198.
16. Brandt I., Joossens J., Chen X., et al. Inhibition of dipeptidyl-peptidase IV catalyzed peptide truncation by Vildagliptin ((2S)-{[(3-hydroxyadamantan-1-yl)amino]acetyl}-pyrrolidine-2-carbonitrile). Biochem Pharmacol 2005, 70:134-143.
17. Scharpé S., De Meester I., Vanhoof G., et al. Assay of dipeptidyl peptidase IV in serum by fluorometry of 4-methoxy-2-naphthylamine. Clin Chem 1988, 34:2299-2301.
18. De Meester I., Vanhoof G., Lambeir A.M., Scharpé S. Use of immobilized adenosine deaminase (EC 3.5.4.4) for the rapid purification of native human CD26/dipeptidyl peptidase IV (EC 3.4.14.5). J Immunol Methods 1996, 189:99-105.
19. Durinx C., Neels H., Van der Auwera J.C., Naelaerts K., Scharpe S., De Meester I. Reference values for plasma dipeptidyl-peptidase IV activity and their association with other laboratory parameters. Clin Chem Lab Med 2001, 39:155-159.
20. Abbott C.A., Yu D.M., Woollatt E., Sutherland G.R., McCaughan G.W., Gorrell M.D. Cloning, expression and chromosomal localization of a novel human dipeptidyl peptidase (DPP) IV homolog, DPP8. Eur J Biochem 2000, 267:6140-6150.
21. Olsen C., Wagtmann N. Identification and characterization of human DPP9, a novel homologue of dipeptidyl peptidase IV. Gene 2002, 299:185-193.
22. Bland J.M., Altman D.G. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1986, 1:307-310.
23. Lankas G.R., Leiting B., Roy R.S., et al. Dipeptidyl peptidase IV inhibition for the treatment of type 2 diabetes: potential importance of selectivity over dipeptidyl peptidases 8 and 9. Diabetes 2005, 54:2988-2994.
24. Matheeussen V., Dubois V., Van Goethem S., et al. Application of clinically used DPPIV-inhibitors in experimental in vivo and in vitro settings. Drugs of the future 2010, 35:261.
25. Beconi M.G., Reed J.R., Teffera Y., et al. Disposition of the dipeptidyl peptidase 4 inhibitor sitagliptin in rats and dogs. Drug Metab Dispos 2007, 35:525-532.
26. D'Amico M., Di Filippo C., Marfella R., et al. Long-term inhibition of dipeptidyl peptidase-4 in Alzheimer's prone mice. Exp Gerontol 2010, 45:202-207.
27. Duttaroy A., Voelker F., Merriam K., et al. The DPP-4 inhibitor vildagliptin increases pancreatic beta cell mass in neonatal rats. Eur J Pharmacol 2011, 650:703-707.
28. Ferreira L., Teixeira-de-Lemos E., Pinto F., et al. Effects of sitagliptin treatment on dysmetabolism, inflammation, and oxidative stress in an animal model of type 2 diabetes (ZDF rat). Mediators Inflamm 2010, 2010:592760.
29. Kawashima S., Matsuoka T.A., Kaneto H., et al. Effect of alogliptin, pioglitazone and glargine on pancreatic beta-cells in diabetic db/db mice. Biochem Biophys Res Commun 2011, 404:534-540.
30. Maiztegui B., Borelli M.I., Madrid V.G., et al. Sitagliptin prevents the development of metabolic and hormonal disturbances, increased beta-cell apoptosis and liver steatosis induced by a fructose-rich diet in normal rats. Clin Sci (Lond) 2011, 120:73-80.
31. Matsui T., Nishino Y., Takeuchi M., Yamagishi S. Vildagliptin blocks vascular injury in thoracic aorta of diabetic rats by suppressing advanced glycation end product-receptor axis. Pharmacol Res 2011, 63:383-388.
32. Matveyenko A.V., Dry S., Cox H.I., et al. Beneficial endocrine but adverse exocrine effects of sitagliptin in the human islet amyloid polypeptide transgenic rat model of type 2 diabetes: interactions with metformin. Diabetes 2009, 58:1604-1615.
33. Mu J., Petrov A., Eiermann G.J., et al. Inhibition of DPP-4 with sitagliptin improves glycemic control and restores islet cell mass and function in a rodent model of type 2 diabetes. Eur J Pharmacol 2009, 623:148-154.
34. Tofovic D.S., Bilan V.P., Jackson E.K. Sitagliptin augments angiotensin II-induced renal vasoconstriction in kidneys from rats with metabolic syndrome. Clin Exp Pharmacol Physiol 2010, 37:689-691.
35. Vaghasiya J., Sheth N., Bhalodia Y., Manek R. Sitagliptin protects renal ischemia reperfusion induced renal damage in diabetes. Regul Pept 2011, 166:48-54.
36. Kim S.J., Nian C., McIntosh C.H. Sitagliptin (MK0431) inhibition of dipeptidyl peptidase IV decreases nonobese diabetic mouse CD4+ T-cell migration through incretin-dependent and -independent pathways. Diabetes 2010, 59:1739-1750.
37. Lamont B.J., Drucker D.J. Differential antidiabetic efficacy of incretin agonists versus DPP-4 inhibition in high fat fed mice. Diabetes 2008, 57:190-198.
38. Maida A., Hansotia T., Longuet C., Seino Y., Drucker D.J. Differential importance of glucose-dependent insulinotropic polypeptide vs glucagon-like peptide 1 receptor signaling for beta cell survival in mice. Gastroenterology 2009, 137:2146-2157.
39. Migoya E.M., Bergeron R., Miller J.L., et al. Dipeptidyl peptidase-4 inhibitors administered in combination with metformin result in an additive increase in the plasma concentration of active GLP-1. Clin Pharmacol Ther 2010, 88:801-808.
40. Raun K., von Voss P., Gotfredsen C.F., Golozoubova V., Rolin B., Knudsen L.B. Liraglutide, a long-acting glucagon-like peptide-1 analog, reduces body weight and food intake in obese candy-fed rats, whereas a dipeptidyl peptidase-IV inhibitor, vildagliptin, does not. Diabetes 2007, 56:8-15.
41. Bergman A.J., Stevens C., Zhou Y., et al. Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers. Clin Ther 2006, 28:55-72.